Gain Therapeutics (GANX) vs Heron Therapeutics (HRTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Gain Therapeutics (GANX) has outperformed Heron Therapeutics (HRTX) over the past year, losing 22.0% versus a loss of 73.5%. Over five years, GANX leads with a -76.7% price change compared with -96.6% for HRTX. Heron Therapeutics is the larger company by market cap ($77.4 million vs $70.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GANX | HRTX |
|---|---|---|
| Share price | $1.63 | $0.4079 |
| Market cap | $70.92M | $77.44M |
| 1-day change | +0.62% | +13.87% |
| YTD return | -49.84% | -72.45% |
| 1-year return | -21.98% | -73.47% |
| 5-year return | -76.73% | -96.62% |
| EPS (TTM) | $-0.50 | $-0.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.34 | $1.58 |
| 52-week low | $1.53 | $0.26 |
| Distance from 52-week high | -62.56% | -74.18% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +343.08% | +1616.11% |
| Average volume | 493.98K | 2.59M |
| Shares outstanding | 43.64M | 189.85M |
| Employees | 20 | 128 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GANX has outperformed HRTX by 51.5 percentage points over the past year.
About Gain Therapeutics
GANX stock →Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
About Heron Therapeutics
HRTX stock →Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
GANX vs HRTX FAQ
Which is bigger, Gain Therapeutics or Heron Therapeutics?
Heron Therapeutics (HRTX) is larger, with a market capitalization of $77.44M compared with $70.92M for Gain Therapeutics (GANX).
Which stock has performed better over the past year, GANX or HRTX?
GANX returned -21.98% over the past 12 months, compared with -73.47% for HRTX (price return, excluding dividends). Past performance does not predict future results.
Are Gain Therapeutics and Heron Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.